February 26, 2018 / 2:24 PM / in 8 months

BRIEF-Hemogenyx Pharmaceuticals Says Lead Candidate Shown To Be Effective In Treatment Of Leukemia

Feb 26 (Reuters) - Hemogenyx Pharmaceuticals Plc:

* HEMOGENYX PHARMA PLC - STMNT RE SHARE PRICE MOVEMENT

* HEMOGENYX PHARMACEUTICALS - ‍CONFIRMS IT HAS FILED A PROVISIONAL PATENT APPLICATION RELATING TO COMPANY’S DEVELOPMENT OF A NEW TYPE OF HUMANISED MICE

* HEMOGENYX PHARMA- ‍FIRST DATA RESULTS HAVE SHOWN CDX BI-SPECIFIC ANTIBODIES ARE CAPABLE OF ATTACKING AND ELIMINATING BLOOD CANCER ACUTE MYELOGENOUS LEUKEMIA IN VITRO​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below